2-(omega-hydroxyalkyl)-3-hydroxy-3-phenylisoindolones



United States Patent 3,454,592 2-(w-HYDROXYALKYL)-3HYDROXY-3- PHENYLISOINDOLONES William J. Houlihau, Mountain Lakes, N.J., assignor to Sandoz Inc., Hanover, NJ.

N0 Drawing. Original application Dec. 18, 1963, Ser. No. 331,372, new Patent No. 3,334,113, dated Aug. 1, 1967. Divided and this application Mar. 8, 1967, Ser. No. 621,413

Int. Cl. C07d 27/28, 57/00; A61k 27/00 US. Cl. 260325 4 Claims ABSTRACT OF THE DISCLOSURE The compounds are of the class of tricyclic compounds having a heterocyclic ring of at least 5 ring atoms fused to the b-side of a 3-phenylphthalimidine, the heterocyclic ring containing one additional hetero atom which is in a 1,3-relationship with respect to the other hetero atom and also ortho to the point of fusion. The compounds are useful as anti-infiammatories and are prepared by reacting an o-benzoylbenzoic acid (or acid halide) with an appropriate w-substituted alkyleneamine.

This application is a division of my copending application Ser. No. 331,372, filed Dec. 18, 1963 now US. Pat. No. 3,334,113.

This invention is directed to compounds which have anti-inflammatory and anti-convulsive activity and thus may be used for either or both activities. The compounds are of particular interest because of their low toxicity.

Said compounds are of one of the basic structures N-(CHRL:

and

III

3,454,592 Patented July 8, 1969 alkyl, e.g. methyl, ethyl, propyl and butyl; lower alkoxy, e.g. methoxy, ethoxy, propoxy and butoxy; amino; chlorine; bromine; fluorine or trifluoromethyl; with the proviso that neither R nor R is trifiuoromethyl when R is trifluoromethyl; and n is either 2, 3, or 4.

These structures, without noting the possible substitucuts, are of one of the types and wherein B is either NH, -O-- or S.

Compounds of structures I to VI are prepared (A) by reacting an o-benzoyl-benzoyl chloride (a substance that can exist in tautomeric forms, such as VII and VIIa) with an til-substituted primary amine and subsequently subjecting the product to ring closure according to the reaction scheme:

I wherein each R is independently either hydrogen or lower VII 6 alkyl, e.g. methyl, ethyl, propyl and butyl; each of R R R R and R is independently either hydrogen, lower on B 4 3 mz-(onmn-nn N-- HR).. W

xx x

or (B) by reacting an o-benzoylbenzoic acid directly with an w-substituted primary amine according to the reaction scheme:

By modification of (B) new intermediates XII are isolatable. This modification proceeds according to the reaction scheme:

(CHR)n-BH X XI VIII fi-OH 0 XII In each of the reaction schemes 1, 2, 3, and 4, B, R and n have the same meanings as previously indicated. Reaction 1 is carried out in a polar solvent (which is inert to the reactants and the reaction product IX) with or without an acid-binding agent, such as pyridine, alkylpyridine and quinoline. Suitable reaction temperatures are from room temperature, i.e. about 20 C., to the boiling point of the solvent employed. It is important to maintain the reaction medium at less than 5 percent by weight (based on the total weight of the amine reactant) of water. The reaction usually takes in excess of 6 hours.

Any polar solvent for the reactants may be used for reaction 1 as long as the solvent is inert Ito, i.e. does not react with, either the reactants or the reaction product. Examples of suitable solvents are: dimethylformamide, diethylformamide, dioxane, chlorbenzene and pyridine.

The product IX of reaction 1 need not be isolated for reaction 2, which is also carried out in a solvent system. The solvent system for reaction 2 contains a catalytic amount of hydrogen ions.

In addition to the solvents contemplated for reaction 1, further solvents, such as benzene, alkylbenzenes, chlorbenzene, dichlorobenzene, cyeloalkanes, tetralin or other high boiling hydrocarbons, are useful for reaction 2. This reaction is likewise conveniently carried out at a temperature from room temperature to the boiling point of the selected solvent system.

To provide a hydrogen ion source, either an organic or inorganic acid may be used. Para-toluenesulfonic acid is preferred, but other acids, such as alkane sulfonic, e.g. methane sulfonic; arylsulfonic, e.g. phenylsulfonic; phosphoric; acid ion exchange resin, e.g. Dowex-SO; acid activated alumino-silicates, e.g. Tonsil, also produce favorable results.

Reaction 3 is conducted in an inert solvent with or without a catalytic amount of hydrogen ions. The solvents are also the same as those indicated for reaction 2.

The intermediates IX for the preparation of compound III are of particular interest. These intermediates have the same substitution on the aromatic rings as noted for compounds III. The corresponding intermediates for compounds I and II are similarly substituted. Intermediates XII are likewise substituted. The latter are prepared by refluxing XI and VIII with toluene and a hydrogen ion source, such as above-exemplified. Intermediate XH is converted to X by refluxing in xylene with a hydrogen ion source.

As reactant VII, examples of suitable compounds are those of the formulae CCl 0-01 0 ll ll VII XIII XIV Cl (FF:

HoCr-O FC1 o-o1 XV XVI F. CH;

HaC-O CCl XVII

6 (EH5 HS(|'JHOHz-CHg-CHNH2 02H; H3 F30 B1 XLI 5 When B is either oxygen or --NH, reactant VIII is I exemplified as in formulae XXIV to XLI with the corresponding changes. HrCa- Reactant XI is the free acid corresponding to reactant VII with respect to possible substitution. The preceding aC- Br \C C exemplification for reactant VII (see formulae VII and i 1 XIII to XXIII) therefore applies equally as well to o reactant XI. Reactant XI can either be made directly in XVIII XIX a manner well known to the art or from the corresponding Br reactant VII.

1 The compounds of this invention (compounds of for- H;OO F mulae I to III) are useful in the alleviation of inflammation. For this purpose oral administration is suitable. Intraperitoneal administration affords protection against I convulsions and/or death caused by convulsions. Both A utilities are evidenced in white male albino mice. For oral Ever 0 F3C 0 administration dosages of 250 milligrams per kilogram C1 of body weight were tolerated and were effective.

fi C1 STRUCTURE I 0 F xx XXI (a) 9b-phenyl-1,2,3,9b-tetrahydro 5H-imidazo[2,1-a] (PC3117 isoindol-S-ones (Foam on These compounds have the ring structure A Br 0 F3(] NH 0-01 fi-m ii 0 XXII XXIII A XLII Each of these compounds is prepared according to well 40 known procedures.

and may be completely unsubstituted or contain selected .Reactalit VIII Saturfited acychc hyqrocarbon sub' substituents in particular positions. Any and/ or all of the stltuted with a primary ammo group and either an OI- I, positions 2 3, 7, 8 and may be substituted. Lower an 1 seicond N group i ffi g? alkyl, preferably of from 1 to 4 carbon atoms, groups cqnnectlpg e puma? i i 1 1 f: s 45 in either or both of the positions 2 and 3 do not adversely stltuent 1S rom.two 0 car OHS m eng 3 may affect the therapeutic properties or the toxicity. Substitube further substltuted with one or more lower alkyl, e.g. tion of the and 4, positions may be by any methyl ethyl propyl butyl groups A reaictant VIII combination of lower alkyl, lower alkoxy, chlorine, can fieacted (a) g i X14111 Ramon 3 and bromine, fluorine and trifluoromethyl groups as long as (b) y reactant m reac Ion there are not trifluoromethyl groups ortho to each other When B is sulfur, examples of reactant VIII are: in the phenyl ring.

HS-CH CH NH HS-CH CHI-NH r P 2 (b) 10b-phenyl-1,2,3,4 tetrahydropyrimido[2,1-a]iso- 3 indo1-6(10bH)-ones XXIV XXV r These compounds have the ring structure 1H5 CH5 CH3 XXVI XXVII HS(|3HOHa-CHz-NH2 HS-OHz-CH-OHr-NH:

XXX XXXI HS-OHz-CHz-CEP-NH: HSCHCH-OHr-NH2 H 3111 Ha 2115 I XXXII XXXIV HS-CHCHzCH-NH2 HSCH--OHaCHz-CHz-NH2 N Hz 2115 CH;

XXXV XXXVI HS-CHa-CH-CHn-CHz-CH: HS-CHz-CHz-CH-CHz-NH: XLIII 2H5 3 1 XXXVH XXXVHI which may be unsubstituted or contain the same substlu- 0 0 NH ents as described for structure XLII in the same relative HSXCHFCIFCHTCIFNH HS CH"CH H 2 positions. The substitution in positions 2, 3 and 4 of 04H a 2 5 XLIII may be the same as that provided for positions 2 XXXIX XL and 3 of XLII.

7 (c) 1lb-phenyl-l,2,3,4,5,11b hexahydro-7H-[1,3]diazepino [2,1-a]isoindol-7-ones These compounds have the ring structure XLIV which also may either be unsubstituted or contain the same substituents as described for structure XLII in the same relative positions. The substitution in positions 2, 3, 4 and 5 of XLIV may be the same as that provided for positions 2 and 3 of XLII.

STRUCTURE II (a) 9b-phenyl-2,3dihydrooxazolo [2,3-a] isoindole-S-ones (b) b-phenyl-2,3,4,10b-tetrahydro-6H[1,3]oxazino[2,3-

a] isoindol-7 1 lbH) ones (c) 11b-phenyl-2,3,4,5-tetrahydro-[1,3]-oxazepino[2,3a]

isoindol-7 (1 1bH)-ones The compounds of these structures correspond with respect to scope of substitution to the compounds of structures XLII, XLIII and XLIV, respectively, as described supra. The sole difference in structure is that the NH- in the 1-position is replaced by --O-.

STRUCTURE III (a) 9b-phenyl-2,3dihydrothiazolo [2,3-a] isoindol-S (9bH) ones (b) 10b-phenyl-2,3,4,l0b-tetrahydro-6H-[1,3]thiazino [2,3-a] isoindol-6-ones (c) 11b-phenyl-2,3,4,5-tetrahydro-[1,3]-thiazepino[2,3-a]

isoindol-7(11bH)-ones The compounds of these structures also correspond with respect to scope of substitution to the compounds of structures XLII, XLIII and XLIV, respectively, as described supra. The sole difference in structure is that the NH- in the 1-position is replaced by S.

The examples which follow are merely illustrative of the invention. Any contemplated combination of substitution may be obtained in the same manner as hereinafter set forth by the corresponding selection of reactants. Compounds of structures I, II and III are prepared in the same manner with only an appropriate change in reactant VHI.

In said examples, unless otherwise specified, all parts are parts by weight, all temperatures are in degrees centigrade and the relationship between parts by weight and parts by volume is the same as that between grams and cubic centimeters.

EXAMPLE 1 2- [s-hydroxyethyl) 3-hydroxy-3 phenylisoindolone Charge a flask with 5.0 grams (g.) (0.082 mole) of ethanolamine, 10.0 g. (0.041 mole) of o-benzoylbenzoyl chloride, 0.2 milliliter (ml.) of pyridine and 50 ml. of dimethylformamide. Maintain at 60 C. for 2 days with continuous stirring. Remove the solvent. The oil residue solidifies on standing. Crystallize the resulting solid from methanol-water.

10.1 g. of Z-(B-hydroxyethyl)3hydroxy-S-phenylisoindolone is obtained in this way. The melting point (M.P.) is 124 to 126 C., and the yield is 87 percent, based on the o-benzoylbenzoyl chloride.

In this example and in subsequent examples the solvent removal is effected 'by means of a rotary evaporator. Either a water or a mechanical pump is employed, and the absolute pressure varies between 0.5 and millimeters (mm.) of mercury (Hg). The temperature varies from room temperature to C.

The stirring in each of the examples is not critical. The rate of stirring, type (e.g. mechanical or magnetic), position and size of stirrer are not critical to the reaction and may be extensively varied. The reaction is efiected even without stirring altogether.

EXAMPLE 2 9b-phenyl-2,3dihydrooxazolo [2,3-a] isoindol-S (9bH) one Admix 10.0 g. (0.037 mole) of Z-(fi-hydroxyethyD-S- hydroxy-3phenylisoindolone (prepared according to Example 1) with 0.5 g. of p-toluenesulfonic acid and 150 ml. of dry toluene in a flask equipped with a Dean-Stark Tube (a device for separating water from the condensate). Reflux until water fails to separate from the condensate. Remove the solvent in vacuo. Crystallize the resultant solid from methanol.

9.4 g. of 9b-phenyl-2,3dihydrooxazolo[2,3-a1isoindol- 5(9bH)-one, M.P. 240 to 245 C., are thus obtained. The yield is percent based on the isoindolone starting material.

Examples 1 and 2 are exemplary of reactions 1) and (2), respectively, and illustrate the two-step method of obtaining the inventive final products. Instead of using compound VII as a starting material for Example 1, the same molar proportion of any of compounds XIII to XXHI is employed in the same way with corresponding results.

EXAMPLE 3a 9b-(3'-amino-4-'chlorophenyl)-2,3-dihydrooxazolo[2,3-a] isoindol-S (9bH) one EXAMPLE 3b 9b- (p-chlorophenyl) -2,3-dihydrooxazolo [2,3-a] isoindol- 5 9bH) one Admix 10.4 g. (0.04 mole) of o-(p-chlorobenzoyl)-benzoic acid with 3.7 g. (0.06 mole) of ethanolamine, 150 ml. of toluene and 0.5 g. of p-toluenesulfonic acid in a flask equipped with a stirrer and a Dean-Stark Tube. Stir and reflux until condensate fails to liberate water. Remove the solvent in vacuo. Crystallize the residue from methanol-water.

6.5 g. 9b-(p-ch1orophenyl)-2,'3-dihydrooxazolo[2,3-a] isoindol-5(9bH)-one, M.P. 71.5 to 74 C., are thus obtained.

Example 3 is exemplary of reaction (3), i.e. the onestep method of obtaining the final products of this invention. The one-step and the two-step methods are alternatives. Either and/ or both can be employed to produce any of the contemplated final products from corresponding starting materials.

EXAMPLE 4 2-( -hydroxypropyl)3-hydroxy-3phenylisoindolone Admix 10 g. (0.13 mole) of 3-aminopropanol, 16.4 g. of o-benzoylbenzoyl chloride, 0.5 ml. of pyridine and 100 ml. of dimethylformamide and stir the resulting solution at 60 C. for two days. Remove the solvent in vacuo. Crystallize resulting solid from methanol-water.

17.4 g. of 2-(' -hydroxypropyl)-3-hydroxy-3-phenylisoindolone, M.P. to 117 C., are thus obtained. This represents a 92 percent yield based on the starting compound VH.

9 EXAMPLE b-phenyl-2,3,4,10b-tetrahydro-6H-[l,3]oxazino[2,3-a] isoindol-6-one Admix 10.0 g. (0.035 mole) of 2-(7-hydroxypropyl)- 3-hydroxy-3-phenylisoindolone (prepared according to Example 4) with 0.5 g. of p-toluenesulfonic acid in 150 ml. of dry toluene in a flask equipped with a Dean-Stark Tube. Reflux until water fails to separate from the condensate. Remove the solvent in vacuo. Crystallize the residue from methanol-water.

8.2 g. of 10b-phenyl-2,3,4,,10b-tetrahydro-6H-[1,3] oxazino[2,3-a]isoindol-G-one, M.P. 122 to 124 C., are thus obtained. This represents an 87 percent yield based on the starting isoindolone.

EXAMPLE 6 10b phenyl 2,3,4,10b tetrahydro 6H [1,3] oxazino 2, 3 -a] isoindol-6-one Admix 11.3 g. (0.05 mole) of o-benzoylbenzoic acid with 5.7 g. (0.075 mole) of 3-aminopropanol, 150 ml. of toluene and 0.1 g. of p-toluenesulfonic acid in a flask equipped with a stirrer and a Dean-Stark Tube. Stir and reflux until condensate fails to liberate water. Remove the solvent vacuo, leaving a viscous residue. Add methanol to the viscous residue to crystallize 9.8 g. of 10b phenyl 2,3,4,10b tetrahydro 6H [1,3]oxazino [2,3-a1isoindol-6-one, M.P. 128 to 129 C.

The infrared spectrum of this product and that prepared from 1-phenyl-2-('yhydroxypropyl)-phthalamide are identical.

EXAMPLE 7 2-( B-hydroxybutyl)-3-hydroxy-3-pl1enylisoindolone Admix 10.0 g. (0.11 mole) of 4-aminobutanol with 13.8 g. (0.056 mole) of obenzoylbenzoyl chloride, 0.5 ml. pyridine and 100 ml. dimethylformamide at 60 C. for two days. Remove the solvent in vacuo, obtaining an oil residue. Shake the oil residue with 200 ml. of water for one hour to form a crystalline precipitate. Recrystallize from dimethylformamide-water.

16.2 g. of 2-(6-hydroxybutyl) -3-hydroxy-3-phenylisoindolone, M.P. 150 to 152 C. are thus obtained. This represents a 97 percent yield based on the starting compound V11.

EXAMPLE 8 1 1b-phenyl-2,3,4,5-tetrahydro 1,3 oxazepino [2,3-a]isoindol-7(11bH)-one Admix 5.0 g. (0.017 mole) of 2-(6-hydroxybuty1)-3- hydroxy-3-phenylisoindolone (prepared according to Example 7) with 0.75 g. of p-toluenesulfonic acid and 75 ml. of dry toluene in a flask with a stirrer and a Dean- Stark Tube. Stir and reflux until water fails to separate. Remove the solvent in vacuo. Crystallize the residue from the methanol-water.

3.8 g. of 11b-phenyl-2,3,4,5-tetrahydro-[1,3]oxazepino [-2,3-a]isoindol-7(1lbH)one, M.P. 133 to 134 C., are thus obtained. This represents an 80 percent yield based on the starting phenylisoindolone.

Examples 1' to 3 illustrate the preparation of compounds of Formula IV wherein B is oxygen. Examples 4 to 6 illustrate the preparation of compounds of Formula V wherein B is oxygen. Examples 7 and 8 illustrate the preparation of compounds of Formula VI wherein B is oxygen.

EXAMPLE 9 equipped with a stirrer and a Dean Stark Tube. Stir and reflux until water fails to separate from the condensate.

Remove the solvent in vacuo. Crystallize the residue from methanol-water.

6.8 g. of 9b-phenyl-1,2,3,9b tetrahydro 5H imidazo [2,l-a]isoindol5-one, M.P. 151 to 153 C., are thus obtained.

(b) Admix 11.3 g. (0.05 mole) of o-benzoylbenzoic acid with 4.2 g. (0.07 mole) of ethylenediamine and 150 ml. of toluene in a flask equipped with a Dean-Stark Tube and a stirrer. Stir and reflux until condensate fails to liberate water. Remove the solvent in vacuo. Crystallize the residue from methanol-water.

10.7 g. of 9b-phenyl-1,2,3,9b-tetrahydro 5H imidazo [2,l-a]isoindol-5-one, M.P. 151 to 152 C., are thus obtained.

Instead of using o-benzoylbenzoic acid as a starting material for this example a comparable amount of any acid corresponding to one of the compounds XIII to XXIII is employed with comparable results.

EXAMPLE 9c 9b-(p-chlorophenyl)-1,2,3,9b-tetrahydro-5H-imidazo [2,1-a] isoindol-S-one Admix 10.4 g. (0.04 mole) of o-(p-chlorobenzoyl)benzoic acid with 3.6 g. (0.06 mole) of ethylenediamine, 150 ml. toluene and 0.5 g. of p-toluenesulfonic acid, in a flask equipped with a Dean-Stark Tube. Stir and reflux until water fails to separate from the condensate. Remove the solvent in vacuo. Crystallize the residue from methanolwater.

5.2 g. of 9b-(p-chlorophenyl)1,2,3,9b-tetrahydro-5H- imidazo[ 2,l-a]isoindol-5-one, M.P. 162 to 163 C., are thus obtained.

EXAMPLE 10a 10b-phenyl-1,2,3,4-tetrahydropyrimido[2,1-a]isoindol- 6 l0bH) -one Admix 22.2 g. (0.10 mole) of o-benzoylbenzoic acid with 8.2 g. (0.11 mole) of 1,3-diaminopropane, 150 ml. of toluene and 1.1 g of p-toluenesulfonic acid in a flask equipped with a stirrer and a Dean-Stark Tube. Stir and reflux until water fails to separate. Remove the solvent in vacuo. Crystallize the residue from methanol.

19.4 g. of 10b-phenyl-1,2,3,4-tetrahydropyrimido[2,l-a] isoindol-6(l0bH)-one, M.P. 181 to 183 C., are thus obtained EXAMPLE 10b 10b- (p-chlorophenyl)-1,2,3,4-tetrahydropyrimido [2,1a]isoindol-6(10bH)-one Admix 10.4 g. (004 mole) of o-(p-chlorobenzoyl)-benzoic acid with 4.44 g. (0.06 mole) of propylene diamine, 150 ml. of toluene and 0.5 g. of p-toluenesulfonic acid in a flask equipped with a Dean-Stark Tube. Stir and reflux until water fails to separate from the condensate. Remove the solvent in vacuo. Crystallize the residue from methanol-water.

9.3 g. of 10b-(p-chlorophenyl)-1,2,3,4-tetrahydropyrimido[2,1-a]isoindol-6(10bH)-one, M.P. 160 to 162 C. are thus obtained EXAMPLE 11a N-(4-aminobutyl)-2-carboxybenzophenone imine Admix 11.3 g. (0.05 mole) of o-benzoylbenzoic acid with 5.0 g. (0.057 mole) of 1,4-diarninobutane, ml. of toluene and 0.6 g. of p-toluenesulfonic acid in a flask equipped with a Dean-Stark Tube and a stirrer. Stir and reflux until condensate fails to liberate water. Remove the solvent in vacuo. Crystallize the residue from methanolether. 8.5 g. of N-(4-aminobutyl)-2-carboxybenzophenone imine, M.P. 200 to 201 C., are thus obtained. Analysis 1 1 calculated for C H N O C, 72.9; H, 7.0; N, 9.4; O, 10.7. Found: C, 72.9; H, 7.0; N, 9.2; O, 11.2.

In a similar way all compounds of the formula wherein each of R, R}, R R R R B and n has the aforedefined meaning, are prepared from corresponding starting materials.

EXAMPLE 11b 11b-phenyl-1,2,3,4,5,1lb-hexahydro-7H-[1,3]diazepino [2,1-a] isoindol-7-one Admix 7.4 g. of N-(4-aminobutyl)-2-carboxy benzophenone imine, 0.3 g. of p-toluenesulfonic acid and 250 ml. of xylene in a flask equipped with a Dean-Stark Tube. Stir and reflux until condensate fails to liberate water. Remove the solvent in vacuo. Crystallize the residue from DMF-methanol-water. 5:9 g. of 11b-phenyl-l,2,3,4,5,11bhexahydro-7I-I[1,3]diazepino [2,1-a]isoindol-7-one, M.P. 180 to 182 C., are thus obtained. Analysis calculated for C H N O: C, 77.7; H, 6.5; N, 10.1; 0, 5.7. Found: C, 77.6; H, 6.8; N, 10.3; 0, 6.0.

This example exemplifies reaction 4. In like manner every compound of Formulae I, II and III is prepared.

EXAMPLE 12 9b-phenyl-2,S-dihydrothiazolo [2,3-a] isoindol-S (9bH -one Admix 6.3 g. (0.055 mole) of mercaptoethylamine hydrochloride with 12.3 g. (0.05 mole) of o-benzoylbenzoyl chloride, 7.9 g. (0.10 mole) of pyridine and 75 ml. of dimethylformamide at 60 C. for two days. Remove the solvent in vacuo. Transfer the resulting residue to a flask containing 150 ml. of toluene and 0.2 g. of p-toluenesulfonic acid and equipped with a stirrer and a Dean-Stark Tube. Stir and reflux until the condensate fails to liberate water. Remove the solvent in vacuo. Crystallize the residue from methanol-water.

5.8 g. of 9b-phenyl-2,3-dihydrothiazolo[2,3-a1isoindol- 5 (9bH)-one, M.P. 103 to 104 C., are thus obtained.

This example illustrates the two-step method for preparing compounds of Formula IV, wherein B is sulfur, without isolating and crystallizing the intermediate. Twostep methods for preparing any of the compounds of Formulae IV to VI can be similarly effected. Compounds of Formulae IV to VI, wherein B is sulfur, are prepared by the same methods as illustrated in Examples 1 to 8 for corresponding compounds, wherein B is oxygen.

In the preparation of said compounds wherein B is sulfur, any of the starting materials exemplified by Formulae XXIV to XLI is employed in place of the corresponding starting material illustrated in any of Examples 1 to 8. Also, corresponding oxygen-and nitrogen-containing amines are employed in the preparation of compounds of Formulae I and II.

It is thought that the invention will be understood from the foregoing description. Various changes may be made in processes, the intermediates and the final products. The processes, the novel intermediates and the final products hereinbefore described are merely illustrative of preferred embodiments of the invention.

What is claimed is:

1. A compound of the formula References Cited UNITED STATES PATENTS 5/1963 Bub 260-325 XR OTHER REFERENCES Truitt et al., J. Med. Chem. (1965), pp. 731-32, vol. 8.

ALEX MAZEL, Primary Examiner.

I. A. NARCAVAGE, Assistant Examiner.

U.S. Cl. X.R. 260-999 

